Delaware joined 49 other states in reaching a settlement with Boehringer Ingelheim Pharmaceuticals, Inc. regarding alleged off-label marketing and misleading promotions of fours of its prescription drugs, including Micardis®, Aggrenox®, Atrovent®, and Combivent®.
The settlement requires the company to make sure its marketing and promotional practices fairly represent its products. According to the Delaware Department of Justice, that entails:
- Limit product sampling of the four drugs to health care providers whose clinical practice is consistent with the product labeling
- Refrain from offering financial incentives for sales that may indicate off-label use of any of the four drugs
- Ensure clinically relevant information is provided in an unbiased manner that is distinct from promotional materials
- Provide that requests for off-label information regarding any of the four drugs are referred to BIPI’s Medical Division.
- The settlement also requires BIPI to make payments to the states and the District Columbia that brought the case.
Delaware will receive $137,000 towards the state’s Consumer Protection Fund.